Q2 2026 13F · SEC CIK 1515070

Tetragon Partners GP Ltd

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $614.3M
Reported positions: 32
Top holdings a year, 3 yrs: +17.8%
Average holding period: 4.0 yrs

Tetragon Partners GP Ltd is a hedge fund that reported 32 positions worth $614.3M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Uipath Inc (PATH, 54.8%), Kolibri Global Energy Inc (KGEI, 5.5%), Autolus Therapeutics PLC (AUTL, 2.5%). A portfolio copying its top holdings returned 17.8% a year over the last 3 years, against 20.4% for the S&P 500.

Tetragon Partners GP Ltd holdings all 32 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Tetragon Partners GP Ltd 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
PATHUipath Inc	54.8%	55.0%	30,950,000	+22.8%	$336.4M
KGEIKolibri Global Energy Inc	5.5%	7.4%	6,834,504	+0.0%	$33.8M
AUTLAutolus Therapeutics PLC	2.5%	2.6%	9,500,000	+0.0%	$15.2M
LYFTLyft Inc	2.4%	2.6%	1,000,000	+0.0%	$14.6M
24477V105Definium Therapeutics Inc	2.2%	0.7%	286,990	+43.5%	$13.5M
WKWorkiva Inc	2.0%	2.9%	250,000	+0.0%	$12.1M
CXMSprinklr Inc	1.8%	2.6%	2,200,000	+0.0%	$11.4M
MBXMbx Biosciences Inc	1.8%	0.9%	203,543	+39.9%	$11.2M
ALKTAlkami Technology Inc	1.8%	New	600,284	—	$10.9M
CLDXCelldex Therapeutics Inc New	1.8%	1.9%	290,441	-7.0%	$10.8M
RLAYRelay Therapeutics Inc	1.7%	0.4%	570,311	+214.1%	$10.7M
ARWRArrowhead Pharmaceuticals in	1.7%	1.6%	130,484	+2.6%	$10.6M
PHVSPharvaris N V	1.7%	1.2%	295,627	+33.4%	$10.2M
ALKSAlkermes PLC	1.6%	1.1%	189,979	+18.9%	$10.0M
IMVTImmunovant Inc	1.6%	1.1%	255,934	+17.1%	$9.9M
SLNSilence Therapeutics PLC	1.4%	0.7%	764,256	+21.3%	$8.4M
DYNDyne Therapeutics Inc	1.3%	0.9%	356,657	+38.2%	$7.9M
IONSIonis Pharmaceuticals Inc	1.3%	0.6%	97,173	+132.7%	$7.7M
AGIOAgios Pharmaceuticals Inc	1.2%	1.1%	205,579	+24.7%	$7.6M
HRMYHarmony Biosciences Holdings I	1.2%	0.7%	201,036	+68.5%	$7.3M
KRYSKrystal Biotech Inc	1.2%	1.0%	19,668	+0.0%	$7.3M
ANNXAnnexon Inc	1.2%	1.4%	1,242,455	-3.9%	$7.1M
CELCCelcuity Inc	1.1%	New	64,110	—	$6.7M
WBDWarner Bros Discovery Inc	1.1%	5.0%	250,000	-72.9%	$6.7M
NKTRNektar Therapeutics	1.0%	1.5%	86,996	-15.6%	$6.1M
AMLXAmylyx Pharmaceuticals Inc	0.9%	0.9%	297,926	-6.3%	$5.4M
ACADAcadia Pharmaceuticals Inc	0.7%	0.6%	167,875	+16.1%	$4.2M
CUECue Biopharma Inc	0.5%	New	93,819	—	$3.0M
SNOWSnowflake Inc	0.4%	0.3%	10,000	+0.0%	$2.5M
ACRSAclaris Therapeutics Inc	0.3%	New	400,000	—	$2.1M
TECXTectonic Therapeutic Inc	0.3%	0.2%	46,516	+23.8%	$1.6M
GLUEMonte Rosa Therapeutics Inc	0.2%	New	56,052	—	$1.4M

What Tetragon Partners GP Ltd bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +43.7% /yr; S&P 500 +20.1%
3 years: +17.8% /yr; S&P 500 +20.4%
5 years: +13.5% /yr; S&P 500 +12.0%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$614.3M	32
Q1 2026	$508.9M	34
Q4 2025	$474.3M	28
Q3 2025	$414.0M	36
Q2 2025	$354.0M	29
Q1 2025	$254.6M	25
Q4 2024	$234.5M	19
Q3 2024	$223.2M	16
Q2 2024	$215.2M	18
Q1 2024	$213.5M	18
Q4 2023	$287.5M	21
Q3 2023	$267.7M	28

Questions about Tetragon Partners GP Ltd's portfolio

What stocks does Tetragon Partners GP Ltd own?

Tetragon Partners GP Ltd's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 32 positions worth $614.3M. The largest are Uipath Inc (PATH) at 54.8%, Kolibri Global Energy Inc (KGEI) at 5.5%, Autolus Therapeutics PLC (AUTL) at 2.5%, Lyft Inc (LYFT) at 2.4% and Definium Therapeutics Inc at 2.2%.

What did Tetragon Partners GP Ltd buy last quarter?

In Q2 2026, Tetragon Partners GP Ltd added a new position in Alkami Technology Inc (ALKT), a new position in Celcuity Inc (CELC), a new position in Cue Biopharma Inc (CUE), a new position in Aclaris Therapeutics Inc (ACRS), a new position in Monte Rosa Therapeutics Inc (GLUE), Relay Therapeutics Inc (RLAY) (+214.1% shares), Ionis Pharmaceuticals Inc (IONS) (+132.7% shares) and Harmony Biosciences Holdings I (HRMY) (+68.5% shares), compared with its Q1 2026 filing.

What did Tetragon Partners GP Ltd sell last quarter?

In Q2 2026, Tetragon Partners GP Ltd sold all of Praxis Precision Medicines I (PRAX), sold all of Soleno Therapeutics Inc (SLNO), sold all of Axsome Therapeutics, Inc. (AXSM), sold all of Maplight Therapeutics Inc (MPLT), sold all of Aardvark Therapeutics Inc (AARD), Warner Bros Discovery Inc (WBD) (-72.9% shares), Nektar Therapeutics (NKTR) (-15.6% shares) and Celldex Therapeutics Inc New (CLDX) (-7.0% shares), compared with its Q1 2026 filing.

How has Tetragon Partners GP Ltd's portfolio performed?

A portfolio copying Tetragon Partners GP Ltd's 20 largest 13F holdings each quarter, from the day each filing was public, returned +17.8% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +43.7% against +20.1%. Over 5 years: +13.5% a year against +12.0%.

When is Tetragon Partners GP Ltd's next 13F filing due?

13F filings are due 45 days after each quarter ends. Tetragon Partners GP Ltd's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.